Developing therapies for Duchenne muscular dystrophy

Our Pipeline

Solid is building a portfolio with the potential to address the many facets of the disease.

Corrective Therapies

Microdystrophin Gene Transfer

Accordion item

Molecule: Biologic

Mechanism: In DMD, the absence or near-absence of the protein dystrophin leads to muscle membrane instability and disruption of the dystrophin glycoprotein complex (DGC). Microdystrophin is a synthetic version of the dystrophin gene that retains its key components and functionality. In preclinical models, its therapeutic administration by adeno-associated virus (AAV) has been shown to stabilize the DGC and rescue muscle function.

Impact on DMD: The large size of the dystrophin gene has historically prevented direct replacement as a therapeutic strategy. Preclinical studies have shown that microdystrophin AAV-mediated gene transfer enables systemic delivery of the truncated gene and has the potential to slow or halt disease progression, regardless of dystrophin gene mutation.

Disease-Modifying Therapies


Accordion item

Molecule: Biologic

Mechanism: Muscular dystrophy is characterized by the replacement of muscle with non-functional fibrotic tissue, which is caused by inflammation and muscle degeneration. The goal of this program is to target a known mediator of fibrosis, TGF-β,  and inhibit its activity. This may be accomplished by targeting a protein known as the latent TGF-β binding protein 4 (anti-LTBP4).

Impact on DMD: anti-LTBP4 has been identified as a genetic modifier of DMD and has been associated with a delayed loss of ambulation. Through the ability of this protein to reduce TGF-β activity, anti-LTBP4 activation has the potential to reduce fibrosis in DMD patients and slow functional decline.

Assistive Devices

Solid Suit

Accordion item

Description: Soft wearable device that can be individualized to allow patients greater mobility and help preserve muscle function.

Impact on DMD: DMD leads to progressive and irreversible muscle loss.  Even with therapeutic intervention, many patients will still require significant physical assistance.  By creating a soft, breathable suit that can be tailored to individual needs, patients may be able to perform daily life activities with greater ease.

More information about Solid?

Please subscribe to receive our latest news